Biopharmaceutical company Hana Biosciences focuses on enhancing cancer care. The company yesterday announced the completion of its phase II rALLY clinical trial for Marquibo for the treatment of adult acute lymphoblastic leukemia (ALL) in 65 patients, exceeding its previous target of 56 patients.

“We would like to thank all the clinical investigators, patients and Hana employees whose efforts have allowed us to not only complete enrollment in our pivotal phase II rALLy trial, but exceed our enrollment target. Enrolling more than the targeted number of patients provides us with important pharmacokinetic data,” Anne Hagey, M.D., chief medical officer of Hana Biosciences stated in the press release. “Our sights are now set on reporting top-line results of the rALLy trial at the 2009 American Society of Hematology Meeting.”

The primary objective of the rALLy clinical trial was to determine the efficiency of a weekly dose of Marqibo based on actual body surface area, as well as evaluation of safety, response duration, and survival rates. The patients were patients who relapsed after two lines of anti-leukemia chemotherapy, including patients who previously underwent stem-cell transplantation.

This past summer, the company announced its preliminary data from the phase II clinical trial to the 44th Annual American Society of Clinical Oncology (ASCO) Meeting, presenting “encouraging” anti-leukemic activity in relapsed adult ALL patients. According to today’s press release, the data presented at ASCO showed promising response and overall survival data with no unexpected toxicity.